1. Home
  2. ASNS vs CANF Comparison

ASNS vs CANF Comparison

Compare ASNS & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ASNS
  • CANF
  • Stock Information
  • Founded
  • ASNS 1998
  • CANF 1994
  • Country
  • ASNS United States
  • CANF Israel
  • Employees
  • ASNS N/A
  • CANF N/A
  • Industry
  • ASNS Telecommunications Equipment
  • CANF Biotechnology: Pharmaceutical Preparations
  • Sector
  • ASNS Telecommunications
  • CANF Health Care
  • Exchange
  • ASNS Nasdaq
  • CANF Nasdaq
  • Market Cap
  • ASNS 10.9M
  • CANF 9.6M
  • IPO Year
  • ASNS 2022
  • CANF N/A
  • Fundamental
  • Price
  • ASNS $0.53
  • CANF $0.39
  • Analyst Decision
  • ASNS Strong Buy
  • CANF Strong Buy
  • Analyst Count
  • ASNS 1
  • CANF 3
  • Target Price
  • ASNS $5.00
  • CANF $10.50
  • AVG Volume (30 Days)
  • ASNS 3.7M
  • CANF 204.7K
  • Earning Date
  • ASNS 11-11-2025
  • CANF 11-27-2025
  • Dividend Yield
  • ASNS N/A
  • CANF N/A
  • EPS Growth
  • ASNS N/A
  • CANF N/A
  • EPS
  • ASNS N/A
  • CANF N/A
  • Revenue
  • ASNS $5,265,000.00
  • CANF $560,000.00
  • Revenue This Year
  • ASNS N/A
  • CANF $461.72
  • Revenue Next Year
  • ASNS $198.35
  • CANF N/A
  • P/E Ratio
  • ASNS N/A
  • CANF N/A
  • Revenue Growth
  • ASNS N/A
  • CANF N/A
  • 52 Week Low
  • ASNS $0.33
  • CANF $0.37
  • 52 Week High
  • ASNS $1.78
  • CANF $2.35
  • Technical
  • Relative Strength Index (RSI)
  • ASNS 49.52
  • CANF 20.76
  • Support Level
  • ASNS $0.38
  • CANF $0.37
  • Resistance Level
  • ASNS $0.75
  • CANF $0.42
  • Average True Range (ATR)
  • ASNS 0.09
  • CANF 0.02
  • MACD
  • ASNS -0.01
  • CANF 0.00
  • Stochastic Oscillator
  • ASNS 29.23
  • CANF 14.33

About ASNS Actelis Networks Inc.

Actelis Networks Inc is a networking solutions company with a mission to enable communication for Internet of Things, or IoT, projects, deployed over wide areas such as cities, campuses, airports, military bases, roads, and rail. Its networking solutions use a combination of newly deployed fiber infrastructure and existing copper and coaxial lines to create a cost-effective, secure, and quick-to-deploy network. Its solutions also offer end-to-end network security to protect critical IoT data, utilizing a powerful combination of coding and encryption technologies, applied as required on both new and existing infrastructure within the hybrid-fiber-copper network. The company operates as one operating segment: developing and marketing access broadband equipment for copper and fiber networks.

About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

Share on Social Networks: